GFH925
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS G12C
Conditions
KRAS G12C
Trial Timeline
Sep 13, 2021 → Dec 20, 2024
NCT ID
NCT05005234About GFH925
GFH925 is a phase 1/2 stage product being developed by Innovent Biologics for KRAS G12C. The current trial status is completed. This product is registered under clinical trial identifier NCT05005234. Target conditions include KRAS G12C.
What happened to similar drugs?
0 of 2 similar drugs in KRAS G12C were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05005234 | Phase 1/2 | Completed |
Competing Products
20 competing products in KRAS G12C